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ARTICLE
Distinct Expression Profiles for PTEN Transcript and Its Splice
Variants in Cowden Syndrome and Bannayan-Riley-Ruvalcaba
Syndrome
Marta S. Sarquis,* Shipra Agrawal,* Lei Shen, Robert Pilarski, Xiao-Ping Zhou, and Charis Eng
Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS) are autosomal dominant hamartomasyndromes.
Germline PTEN mutations have been associated with 85% of CS cases and 65% of BRRS cases and also with other
disorders, which are collectively referred to as the “PTEN hamartoma tumor syndrome.” The human PTEN gene has been
previously found to express two naturally occurring splice variants (SVs). Recently, we identified eight novel naturally
occurring PTEN SVs that result in different downstream signaling effects: SV3a, SV3b, SV3c (inclusion of various lengths
of intron 3 3′ of exon 3), SV5a, SV5b, SV5c, SV5d (inclusion of various lengths of intron 5 3′ of exon 5), and SVDEx6
(deletion of exon 6). We therefore sought to characterize the relative expression of 5′, middle, and 3′ full-length PTEN
mRNA (FL-PTEN) and also of these eight PTEN SVs in 85 (65 female and 20 male) patients with CS/BRRS (with or without
PTEN mutations) compared with 27 controls, using a SYBR green quantitative polymerase chain reaction method. Sig-
nificantly reduced FL-PTEN levels were found in the probands, compared with those of controls ( ). Apart fromP ! .01
FL-PTEN, SV3a is the most consistently relatively underexpressed in patients compared with controls. The patients showed
relative underexpression of SV3a and SV3b and overexpression of SV5b ( , , and , respectively).Pp .005 Pp .02 Pp .04
Indeed, there appears to be an SV expressional genotype-phenotype correlation in which the SV expressional profiles
are distinct among CS, CS-like, and BRRS. The reduced FL-PTEN transcript expression, associated with differential ex-
pression of PTEN SVs, regardless of PTEN mutation status, supports the concept that modulation of PTEN inactivation
may also occur at the transcription level influencing the specific phenotypes seen in these syndromes.
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Cowden syndrome (CS [MIM 158350]) and Bannayan-
Riley-Ruvalcaba syndrome (BRRS [MIM 153480]) are au-
tosomal dominant disorders characterized by hamartomas
and an increased risk of breast, thyroid, and uterine can-
cers. Germline PTEN mutations have been associated with
85% of CS cases and 65% of BRRS cases1–3 as well as other
disorders, which are collectively referred to as the “PTEN
hamartoma tumor syndrome” (PHTS).4 PTEN (phospha-
tase, tensin homologue, deleted on chromosome 10) en-
codes a tumor suppressor, which mediates cell-cycle arrest
and apoptosis.5 It is a dual-specificity phosphatase that
dephosphorylates both lipid and protein substrates.6 Its
major lipid phosphatase activity acts on phosphatidyli-
nositol(3,4,5)triphosphate, yielding phosphatidylinosi-
tol(4,5)biphosphate.7 Inactivation of PTEN allows consti-
tutive and unregulated activation of the Akt/protein
kinase B and mitogen-activated protein kinase (MAPK) sig-
naling pathways, resulting in uncontrolled proliferation.8,9
In addition to its growth-suppressive function, PTEN de-
phosphorylates focal adhesion kinase, resulting in inhi-
bition of cell spreading and migration.10
RNA splicing is essential for the generation of protein
diversity and can also have regulatory functions. During
splicing, alternative usage of splice donor or acceptor sites
can lead to various exons and introns being skipped or
retained, creating a diverse array of mRNAs from a single
pre-mRNA, a process referred to as “alternative RNA splic-
ing.”11 More than half of all human genes generate mul-
tiple mRNAs by alternative splicing, and ∼80% of those
result in changes in the encoded protein.12 For the ma-
jority of alternative splice events, however, their func-
tional significance is still unclear.13
The human PTEN gene has been found to express splice
variants involving deletions from the normal coding se-
quence but also the inclusion of intronic segments.14 Be-
cause these variants were identified in normal and cancer
tissues, the significance of these variants in carcinogenesis
has become a controversy.15 Patterns of alternative splicing
can be tissue, stimulus, or disease specific, and thus the
presence or levels of specific alternatively spliced mRNAs
may provide useful biomarkers, even without knowledge
of their activities.13 A large number of cancer-related genes
exhibiting alternative splicing have been characterized,
such as BRCA1, MDM2, and WT1.13,16 These splice variants
could either be causative of disease; be involved in disease
development; influence the extent of tumor invasion, the
Table 1. Germline PTEN Mutation or Variant and Phenotype of the Patients in the Study
Group and Sample Location Mutation or Variant Phenotype
Sequence variant:
SCP12* Promoter region 903 G/A CS-like
SCP19* Promoter region 903 G/A CS
SCP20* Promoter region 903 G/A CS
SCP36* Promoter region 903 G/A Breast cancer and glycogenic
acanthosis
SCP38* Promoter region 903 G/A CS-like
SCP39* Promoter region 903 G/A CS-like
SCP43* Promoter region 903 G/A CS-like
SCP51* Promoter region 903 G/A CS-like
SCP57* Promoter region 903 G/A Breast hamartomas
SCP58* Promoter region 903 G/A CS-like
SCP63* Promoter region 903 G/A CS-like
SCP14* Promoter region 1026 C/A CS
SCP42* Promoter region 1026 C/A CS-like
SCP60* Promoter region 1026 C/A CS-like
SCP64* Promoter region 1026 C/A CS
SCP56* Promoter region 1026 C/A CS-like
SCP23* Promoter region 1026 C/A CS-like
SCP26* Promoter region 1026 C/A CS
SCP25* Promoter region 1084 C/T CS
SCP28* Promoter region 1084 C/T CS-like
SCP4* Exon 6 L193L (CTG193CTA) CS
SCP66* Exon 4 T78T (ACC78ACT) CS-like
SCP59* Exon 2 G44G (GGC44GGT) CS-like
Germline PTEN mutation positive:
SCP45* Promoter region 843 C/T CS-like
SCP67* Promoter region 843 C/T CS-like
SCP72* Promoter region 970 T/G CS-like
SCP13* Promoter region 1142 C/T CS
SCP24* IVS1 IVS1 35 C/T Juvenile polyps
SCP2* Exon 1 T26P (ACC26CCC) CS-like
SCP32* Exon 1 R15S (AGA15AGT) CS-like
SCP40* Exon 1 Y16X (TAT16TAA), Q17X (CAA17TAA) BRRS
SCP47* Exon 1 Y16X (TAT16TAA), Q17X (CAA17TAA) CS
SCP71* Exon 1 I32N (ATT32AAT) CS/BRRS overlap
SCP46* IVS2 IVS2 38 ins G BRRS
SCP16* IVS2 IVS2 31 G/T CS
SCP11* Exon 3 Y68X (TAC68TAA) BRRS
SCP15* Exon 5 445 ins A, IVS4 29 insT CS-like
SCP6* Exon 5 445 ins A CS-like
SCP35* Exon 5 445 ins A CS-like
SCP27* Exon 5 G132V (GGT132GTT) CS
SCP18* Exon 5 315 del T BRRS
SCP21* Exon 5 R130Q (CGA130CAA) BRRS
SCP37* Exon 5 L152P (CTA152CCA) CS-like
SCP54* Exon 5 C136Y (TGT136TAT) CS
SCP1* Exon 5 R130X (CGA130TGA) No signs reported
SCP3* Exon 5 R130X (CGA130TGA) CS
SCP5* Exon 5 R130X (CGA130TGA) CS
SCP7* Exon 5 R130X (CGA130TGA) No signs reported
SCP8* Exon 5 R130X (CGA130TGA) No signs reported
SCP10* Exon 6 C211X (TGC211TGA) CS
SCP53* Exon 6 C211X (TGC211TGA) CS
SCP52* Exon 6 549 ins A BRRS
SCP55* Exon 6 604–610 del 7 (ACTATTC) BRRS like
SCP9* Exon 7 706–8 GAC/TTGT CS
SCP49* Exon 7 683 del A No information
SCP61* Exon 7 Q245X (CAG245TAG) CS
SCP68* Exon 7 K260R (AAA260AGA) Glycogenic ancanthosis
SCP33* Exon 8 972 del T CS
SCP65* Various IVS3 39 A/G, IVS4 29 ins T,
IVS7 1 del G
CS
SCP41* Various 1084 C/T and 9 C/G CS-like
SCP62* Various 1084 C/T and 9 C/G CS-like
SCP22 Various 903 G/A and L112V (CTA112GTA) CS-like
SCP17* Various 903 G/A and R130Q (CGA130CAA) CS
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Figure 1. Diagram showing splice variants of PTEN: SV3a, 3b, 3c, 5a, 5b, 5c, 5d, and DEx6. With the exception of SVDEx6, all variants
consist of insertions of intronic regions (represented by the bars with different patterns) following the 3′ end of the exons. SVDEx6
was generated by the deletion of the entire exon 6. See table 2 for more details. Ex p exon.
status of lymph node involvement, and distant metastasis;
or act as surrogate markers.13,17
Recently, we identified eight novel naturally occurring
PTEN splice variants (SVs) that result in different down-
stream signaling effects.18 We therefore sought to char-
acterize the relative expression levels of these eight PTEN
SVs in a large series of germline PTEN mutation-positive
and -negative patients with PHTS spanning various phe-
notypes compared with the levels in normal controls. We
also quantified the expression of full-length (FL) PTEN
mRNA, using three sets of primer pairs encompassing the
5′ end, middle, and 3′ end of PTEN. In addition to increas-
ing our fundamental understanding of the impact of var-
ious splicing alterations on modulation of the protean
manifestations of CS/BRRS, we hoped to identify specific
splice variants that could help identify individuals with
CS/BRRS phenotypes regardless of mutation status.
Material and Methods
Human Subjects and Samples
Eighty-five subjects (65 female and 20 male) were enrolled in a
PTEN research study by referral from U.S. and international cen-
ters. All samples were acquired with informed consent in accor-
dance with protocols approved by the human subjects protection
committees of the respective institutions.
For the purposes of this study, a series of PHTS-affected indi-
viduals with germline PTEN mutations, a series of CS/BRRS-
affected individuals without mutations, and a series of normal
controls were required. Among the 85 patients in this study, 22
have no detectable germline PTEN mutations, and 63 have var-
ious germline PTEN alterations throughout the gene, comprising
43 with pathogenic mutations and 20 with variants (table 1). The
27 normal controls were defined as having no documented ill-
ness, no CS/BRRS phenotype or CS/BRRS features, and no PTEN
mutation. The 63 subjects who were PTEN alteration positive were
included in this study regardless of clinical syndrome name. Most
(28) had classic CS and BRRS, 26 had CS-like, and 1 had BRRS-
like. Of the 63 patients with PTEN germline pathogenic muta-
tions, 8 could not be classified as having CS/CS-like or BRRS/BRRS-
like, because each had only hamartomatous/hyperplastic polyps,
breast hamartomas, breast cancer, or breast cancer plus glycogenic
acanthosis as the sole clinical manifestation. Three patients had
no reported clinical findings but had been found to carry the
same mutation (R130X) carried by a sibling, and one patient had
no specific clinical information available. The 22 patients who
were PTEN mutation negative were all classified as having classic
CS (by the International Cowden Consortium operational diag-
nostic criteria)4 or BRRS.
RNA Extraction
Lymphocyte pellets were separated from total peripheral blood
of patients and normal controls by use of red blood cell lysis
buffer (89.9 g NH4Cl, 10.0 g KHCO3, and 2.0 ml 0.5-M EDTA) and
were resuspended in PBS that was subsequently aspirated after
centrifugation. The pellet could then be immediately processed
for RNA extraction or stored at 80C until further use. Total
RNA was extracted using Versagene (Gentra Systems) total RNA
purification kit, according to the manufacturer’s instructions.
mRNA Expression of FL-PTEN and Its Splice Variants
We studied the patients and the normal controls for expression
of eight novel SVs of PTEN identified in our lab—namely, SV3a,
SV3b, SV3c, SV5a, SV5b, SV5c, SV5d, and SVDEx6.18 With the
exception of SVDEx6, all variants consisted of insertion of in-
tronic regions following the end of the exons (fig. 1 and table 2).
For example, SV3a was generated by alternative splicing of the
end of exon 3 (genomic sequence 83526) to a splicing acceptor
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Table 2. Size and Position of the Intronic
Insertions or Exon Deletions That Generated
the Splice Variants
Splice Variant Description Change
SV3a IVS31991 to 2019 Ins 29 bp
SV3b IVS31991 to 2042 Ins 52 bp
SV3c IVS34660 to 4699 Ins 40 bp
SV5a IVS53617 to 3654 Ins 38 bp
SV5b IVS51377 to 1703 Ins 327 bp
SV5c IVS59356 to 9514 Ins 158 bp
SV5d IVS53028 to 3088 Ins 60 bp
SVDEx6 Exon 6: 2422 to 2563 Del 142 bp
NOTE.—For example, SV3a was generated by the in-
sertion of 29 bp (from intron 3 sequence) at 1,991 bp
following the 3′ end of exon 3 and ending at 2,019
bp following the 3′ end of exon 3. SVDEx6 was the
only one generated by a deletion of the entire exon
6, from nucleotide 2422 to 2563.
Table 3. Primers and PCR Conditions Used to Amplify the
PTEN Transcript or Its Splice Variants
PTEN Targets
and Primers Sequence
Annealing
Temperature
(C)
No. of
Cycles
1-2: 55 40
1F CAGCCATCATCAAAGAGATCG
2R TTGTTCCTGTATACGCCTTCAA
3-4-5: 59 40
3F TGGATTCAAAGCATAAAAACCA
4–5R AAAAGGATATTGTGCAACTCTGC
7-8: 59 40
7F TCCACAAACAGAACAAGATG
8R CTGGTCCTGGTATGAAGAAT
SV3a: 59 48
1F CAGCCATCATCAAAGAGATCG
IVS3a R CTTTCAGCACAATTAACTTCTCT
SV3b: 59 44
1F CAGCCATCATCAAAGAGATCG
IVS3b R CTGTGTGACCTTGTTCAACTCA
SV3c: 60 48
1F CAGCCATCATCAAAGAGATCG
IVS3c R GCAGTACCCTGGTAACTCCAA
SV5a: 60 48
4F TCTTTGTGCTGAAAGACATT
IVS5a R AGCCTTCTCTTGGATTTAATTTGGACTT
SV5b: 61.2 48
4F TCTTTGTGCTGAAAGACATT
IVS5b R CGCCTCGGCCTCCCAAAGT
SV5c: 59 38
4F TCTTTGTGCTGAAAGACATT
IVS5c R GGCCTCTACAAGGTCAGGATCAT
SV5d: 60 48
4F TCTTTGTGCTGAAAGACATT
IVS5d R GCCTTCTCTTGGATTTAATTTGG
SVDEx6: 59 42
5–7F AGGACCAGAGACAAAAAGATC
8R CTGGTCCTGGTATGAAGAAT
NOTE.—The first three pairs define exonic regions and, hence, FL-PTEN,
whereas the other primer pairs define the splice variants studied. Primer3
was used for design.
site within the third intron (intron C), which thus inserted 29
bp (85517–85545) of the genomic sequence (1,991 bp down-
stream of the end of exon 3). The other SVs were generated sim-
ilarly, with inclusions of various lengths of intron 3 3′ of exon 3
(SV3a, 3b, and 3c) or inclusions of intron 5 3′ of exon 5 (SV5a,
5b, 5c, and 5d) (table 2). SVDEx6 was generated by the exclusion
of the entire exon 6. To compare the expression of these SVs with
FL-PTEN mRNA, we also measured, in all the patients and con-
trols, three regions representing the 5′ end, middle, and 3′ end of
the gene: exons 1 and 2 (1-2); exons 3, 4, and 5 (3-4-5); and exons
7 and 8 (7-8).
cDNA Synthesis Reaction
One microgram of RNA extracted from the patients and normal
controls was treated with DNase at room temperature by use of
2 U amplification-grade DNase (Invitrogen). DNase in the reac-
tion mix was inactivated by EDTA and heating at 65C for 5 min.
cDNA was synthesized using Superscript Reverse Transcriptase II
(Invitrogen) and random primers (Invitrogen), according to the
manufacturer’s instructions.
SYBR Green Quantitative PCR
Before the relative quantification procedure, the cDNA samples
were amplified using HotstarTaq master mix (Qiagen) and primers
for PTEN exons and splice variants (table 3). PCR was performed
in a Peltier Thermal Cycler-200 (MJ Research, Bio-Rad) by use of
specific conditions for each primer pair, optimized to ensure that
a single band of the appropriate length was amplified (table 3).
Products were analyzed on a 2% agarose gel stained with ethidium
bromide.
Relative quantification of FL-PTEN mRNA and its splice variants
was performed using a SYBR green quantitative PCR method for
comparison between patients and normal controls. Compared
with b-actin, the GAPDH gene primer pair showed similar am-
plification efficiency to FL-PTEN and its splice variants in the
cDNA dilution standardization experiment (fig. 2), and thus
GAPDH was chosen as the control gene. Five serial dilutions of
cDNA were amplified using gene-specific primers. The DCT was
calculated for each cDNA dilution. The data were fit using linear
regression analysis. If the absolute value of the slope is close to
zero, the efficiencies of the target and reference genes are similar,
and the DDCT calculation for the relative quantification of the
target may be used.19 The reactions were performed using SYBR
Green PCR MasterMix (Bio-Rad) in the iCycler apparatus (Bio-
Rad Laboratories). Amplification reactions, in a final volume of
25 ml, included 12.5 ml of SYBR Green PCR MasterMix (Bio-Rad),
∼0.3 mg of cDNA, and 10 mM of each primer (forward and re-
verse). For the quantification of expression of FL-PTEN mRNA
transcript, three sets of primer pairs were used that represented
the beginning, middle, and end of the gene: exons 1 and 2 (1-
2); exons 3, 4, and 5 (3-4-5); and exons 7 and 8 (7-8). For the
splice variants with intronic insertions, the forward primer was
in the exon preceding the inserted intron sequence, and the re-
verse primer was in the inserted intronic sequence (table 3). For
SVDEx6, the forward primer included the ending and beginning
sequence of exons 5 and 7, respectively, and the reverse primer
was within exon 8. In all cases, we performed 80 cycles of melting,
to verify the absence of nonspecific products. All the reactions
were performed in triplicate, and the comparative CT method was
used for the quantification of the expression for each segment,
by use of GAPDH as a normalization control gene. All the reac-
tions were done with a negative control to ensure that we had
no contamination. One normal control sample was chosen to be
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Figure 2. Plot of the log cDNA dilution versus DCT. The plots
show the efficiency of amplification of the target sequences (SV3a,
3c, 5b, and 5c) and internal control (GAPDH) examined using SYBR
green quantitative PCR. Five serial dilutions (X-axis) of cDNA were
amplified using gene-specific primers. The DCT was calculated for
each cDNA dilution. The data were fit using linear regression
analysis.
Table 4. P Values (from t Test) from the
Comparisons of Relative Expression of SVs between
Patients and Controls Grouped According to Clinical
Phenotype, Mutation Status, and Mutation Type
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
used as a standard control for all the reactions with the patient
samples. After each reaction, the products were analyzed on a 2%
agarose gel stained with ethidium bromide, to rule out the pres-
ence of any extra amplified bands.
To assure the segments were being correctly amplified, sequenc-
ing of randomly chosen real-time PCR products was performed
using dGTP technology and the ABI 3730 analyzer (Applied Bio-
systems, Perkin-Elmer) according to the manufacturer’s recom-
mendation. The Sequencher software package (version 4.2
[GeneCodes]) was used for sequence analysis.
Results
To address the hypothesis that differential expression of
naturally occurring PTEN SVs will occur in patients with
CS/BRRS compared with controls, we performed relative
quantitation of SVs, FL-PTEN transcript, and the house-
keeping GAPDH in 85 patients (63 with germline PTEN
variation, comprising 43 with proven pathogenic muta-
tions and a further 20 with variants of unknown signifi-
cance [VUS]) and 27 normal controls, in a blinded fashion.
After molecular analyses were complete, phenotype and
mutation status were unblinded for statistical analysis (ta-
ble 1).
FL-PTEN transcript and all the naturally occurring splice
variants were present in both patients and controls and
showed significant differences in levels of expression in
each of the groups studied (figs. 3 and 4 and table 4).
Among the SVs, in both patients and controls, the highest
level of relative expression was seen for SV3c, and the
lowest relative expression was seen for SV5d (fig. 3). The
group comprising all patients showed relative underex-
pression of FL-PTEN transcript, most accurately reflected
in the exon 7–8 amplicon, compared with normal controls
(figs. 3 and 4). Interestingly, differential expression of spe-
cific SVs was evident in the patient group compared with
controls (figs. 3 and 4). SV3a and SV3b were relatively
underexpressed in patients compared with controls (Pp
and , respectively; figs. 3 and 4). In contrast,.005 Pp .002
SV5b was slightly overexpressed in the patients compared
with normal controls ( ; fig. 4).Pp .04
The patients were then subdivided according to the
three major phenotypic groups (30 with CS, 39 with CSL,
and 7 with BRRS) and were analyzed for relative expression
of FL transcript and the various SVs (fig. 4). Just as with
the entire patient group as a whole, FL transcript and SV3a
expression levels were reduced in each of the phenotypic
groups—CS ( ), CSL ( ), and BRRS (Pp .001 Pp .02 Pp
)—compared with controls. The CS group and CSL.02
group, but not the BRRS group, each showed a higher
expression of SV5b ( and .048, respectively; fig.Pp .003
4). Interestingly, SV3b expression, which was found to be
reduced in the entire patient group, showed a relative un-
derexpression in only the CSL group ( ; fig. 4),Pp .0395
not in the CS or BRRS group. Further, SV5a was signifi-
cantly overexpressed in only the CSL group compared
with controls ( ; fig. 4). This observation con-Pp .0275
trasts with the entire patient group, which did not show
differential expression of SV5a.
For further analysis, the 85 patients were regrouped into
three by germline PTEN status—namely, the PTEN mu-
tation-positive group ( ), PTEN mutation-negativenp 43
group ( ), and VUS group ( ). Each of the threenp 22 np 20
groups showed relative underexpression of FL transcript
compared with controls ( ; fig. 4). Interestingly, theP ! .02
mutation-positive and VUS groups but not the mutation-
negative group showed significantly lower expression lev-
els of SV3a ( ) compared with controls (fig. 4). There-P ! .02
fore, decreased expression of SV3a seen in patients was
not specific for any of three major phenotypes but was
an important marker for those with promoter alterations
that, theoretically, would not interfere with PTEN func-
tion. Furthermore, the VUS group but not the mutation-
positive or mutation-negative group had a significantly
lower expression level of SV3b ( ). Of note, PTENP ! .01
mutation-negative patients had a significantly higher
SV5b expression level ( ) compared with controls, aP ! .02
difference not seen in either the mutation-positive or the
VUS groups.
We analyzed SV expression levels by dividing the pa-
tients who had PTEN mutations according to mutation
type (missense, nonsense, frameshift, etc.). Patients with
germline truncating mutations (nonsense and frameshift)
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Figure 3. Log-transformed expression values (Y-axis) of FL-PTEN (1-2, 3-4-5, and 7-8) and different splice variants (SV3a, 3b, 3c, 5a,
5b, 5c, 5d, and DEx6) for controls (red triangles) and patients (black circles). Table 4 gives the P values (from t test). See text and
figure 4 for more details.
Figure 4. Two-color “heat map” representing relative expression
of SV3a, SV3b, SV5a, SV5b, SV5d, and FL (7-8) transcripts in all
cases, phenotypic subgroups, and mutation-status subgroups com-
pared with normal controls. Green boxes represent significant
( ) relative underexpression; red boxes, significant overex-P ! .05
pression; and black boxes, no difference in relative expression
compared with controls. Mut Neg.p mutation negative; Mut Pos.
p mutation positive; NS p nonsense mutation; MS p missense
mutation; FS p frameshifting mutation.
but not those with missense mutations had reduced levels
of FL transcript, as expected (fig. 4). We found that patients
with missense mutations had lower expression levels of
SV3a and SV3b ( ) but higher SV5a expression levelsP ! .01
( ; fig. 4) than those of controls. Therefore, our dataP ! .05
together show that the relative underexpression of variant
SV3b was more specific to patients with CSL when pro-
moter alterations (VUS) were present. Patients with non-
sense mutations had lower expression levels of SV3a,
SV3b, and SV5d compared with those of controls (P !
; fig. 4). Interestingly, this differential SV expression.02
was not noted among patients with frameshifting muta-
tions (microinsertions or deletions) who had decreased FL-
PTEN only.
Discussion
There has been considerable interest in alternatively
spliced transcripts and their role in normal development
and pathological conditions.20–22 Because of their presence
in normal tissues, it is natural to suppose that they might
have important biological functions. In addition, increas-
ing evidence suggests that alternative RNA processing is
involved in human cancer during transformation and/or
acquisition of metastatic potential.17,21 Different SV pro-
files could also have implications in the risk of developing
cancer as well as potentially influence prognosis and re-
sponse to therapies.11,20 The use of alternative splice sites
might result in the inappropriate expression of different
protein isoforms that ultimately would affect cellular
physiology and consequently contribute to tumorigenesis.
While somatic alternative splicing and SVs have been
studied extensively in neoplasia, few studies, if any, have
systematically analyzed splice variation in the germline of
those with heritable cancer syndromes. We have found
eight novel naturally occurring splice variants transcribed
from PTEN (fig. 1). Of the eight SVs, five show differential
expressional levels in CS/BRRS cases compared with nor-
mal controls (fig. 4). The observation that FL-PTEN tran-
script is underexpressed in cases compared with normal
controls, except for those with missense mutations (this
last group included all promoter mutations), serves as a
good internal experimental control. The fact that the
frameshift mutation group, compared with the control
group, showed relative underexpression of only FL tran-
script, with no differences in expression of any SV (fig. 4),
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also serves as an experimental control. Consistent with
the literature, frameshifting mutations result in transcripts
that undergo rapid nonsense-mediated degradation.23
Thus, the observation of underexpression of only FL tran-
script in our patients with germline frameshift mutations,
which likely reflects mainly the remaining wild-type al-
lele, is consistent with our hypothesis. In the context of
our observation of differential SV expression shown in
figure 4, this particular observation may give circumstan-
tial evidence that the differential SV expression seen in
the other subgroups (fig. 4) reflects alternative splice usage
from the affected allele.
Inspection of figure 4 reveals virtually unique SV relative
expression profiles between cases and controls and among
the various groups of cases. Except for the frameshift mu-
tation group and the mutation-negative group, which had
similar profiles, every group had a unique profile (fig. 4).
Apart from FL transcript, SV3a is the most consistently
relatively underexpressed in cases and among all groups
compared with controls. The cases show relative under-
expression of SV3a and SV3b and overexpression of SV5b.
It is interesting to note that the SV5b overexpression pro-
file is contributed by mainly patients with CS who com-
prise the majority of cases and who would also have the
highest likelihood of being mutation positive. Indeed,
there appears to be an SV expressional genotype-pheno-
type correlation in which the SV expressional profiles are
distinct among CS, CS-like, and BRRS cases.
Germline VUS in cancer susceptibility genes are a di-
agnostic dilemma in clinical practice. Here, we demon-
strate that the relative SV expressional profile in the VUS
group did not mirror that in the controls but, instead,
showed relative underexpression of SV3a and SV3b in ad-
dition to FL transcript. This only underscores our lack of
understanding of the complex downstream consequences
of VUS. However, our observations may suggest that SV
typing may help resolve the diagnostic dilemma, if our
data can be independently confirmed. Germline muta-
tion-negative cases in any heritable syndrome represent a
challenge in the practice of clinical cancer genetics and
genetic counseling as well. Our study shows that PTEN
mutation-negative CS/BRRS cases have a relative SV ex-
pressional profile similar to that of the frameshift muta-
tion group, for which only FL transcript, but no SV, was
underexpressed compared with normal controls. While it
could be argued that there is a variant in the promoter
leading to relative underexpression of PTEN, our muta-
tion-negative cases were not found to have any variants
in the PTEN promoter. However, it is altogether possible
that PTEN has an as-yet-unrecognized alternative pro-
moter(s), and germline variants/mutations there may con-
tribute to our observed profile. Nonetheless, again, relative
transcript quantitation may prove to be a useful diagnostic
adjunct if our data can be independently replicated.
While we have demonstrated that FL-PTEN transcript
and its SVs show distinct relative expressional profiles in
CS/BRRS, the mechanism by which these SVs lead to or
modulate the phenotype is currently unknown. We can
only postulate that SVs could play a role in CS/BRRS patho-
genesis in at least two non–mutually exclusive ways.
First, SVs may play an indirect role by mediating, either
by facilitating or interfering with, FL-PTEN transcription
and/or translation. And it is this fine balance among SV3a,
SV3b, SV5a, SV5b, and SV5d that modulates the rate or
quantity of FL transcription or translation. Second, SVs
may actually be translated into protein and exert their
effect in the signaling pathways downstream of PTEN. In
a recent study, we functionally analyzed the PTEN SVs by
measuring PTEN’s downstream readouts—that is, the ef-
fect that expression of these SVs has on phosphorylation
of Akt and cyclin D1 promoter activity. We have dem-
onstrated that SV5b protein increases cyclin D1 promoter
activity in vitro, which is the opposite of PTEN protein
action.18 This corroborates our observation here that SV5b
is overexpressed in cases, particularly CS and CS-like, and
in mutation-positive patients (fig. 4). We also have shown
that overexpression of SV5a resulted in slightly decreased
P-Akt levels and decreased cyclin D1 promoter activity as
measured by the reporter firefly luciferase.18 Therefore,
SV5a functions in a manner similar to PTEN.18 Superfi-
cially, these functional data appear contradictory to our
current observations that SV5a is relatively overexpressed
in CS-like cases and the missense mutation group. How-
ever, the CS-like phenotype is milder (i.e., missing phe-
notypic criteria) than classic CS.24 Hence, we may specu-
late that SV5a, which mimics PTEN downstream action,
may partially compensate for altered PTEN function and
thus modulate phenotype. Similarly, we postulate that
missense mutations result in PTEN protein that can act in
a dominant negative manner (as has been shown, at least
in vitro9), and so relative overexpression of SV5a would
worsen the dominant negative effect in cases with germ-
line missense mutations.
In conclusion, our data favor the concept that reduced
FL-PTEN transcript expression, associated with differential
expression of PTEN SVs, regardless of PTEN mutation
status, may modulate its action and therefore lead to dif-
ferent phenotypes. This influence can occur at the tran-
scription or translation level of PTEN, producing partially
active transcripts that could act in the same way as the
primary protein or in opposition to the wild-type allele,
having, in this latter case, a dominant negative action.
The study of these variants with their characterization and
quantification is particularly important in PTEN muta-
tion-negative patients and patients with VUS, given that
we could demonstrate that these groups have distinct pro-
files compared with those of normal controls. If confirmed
by other studies, we might be able to use these novel data
to help establish the diagnosis of CS/BRRS regardless of
the mutation status. The complete comprehension of the
mechanism involved in the alternative splicing, its cor-
relation with normal or mutant PTEN, and the differential
downstream signaling not only may add to the funda-
mental understanding of PTEN’s complex pathways in
30 The American Journal of Human Genetics Volume 79 July 2006 www.ajhg.org
health and disease but also may help us understand the
resultant phenotype of the different syndromes associated
with this gene.
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.nlm.nih.gov/Omim/ (for CS and BRRS)
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